Toshiyuki Yano
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Toshiyuki Yano has a total of 222 co-authors. Here are the top co-authors by number of shared publications:
Katsuhiko Ohori
Division of Cardiovascular-Kidney-Metabolic Medicine, Department of Internal Medicine, Sapporo Medical University School of Medicine
30 shared publicationsTetsuji Miura
Department of Clinical Pharmacology, Faculty of Pharmaceutical Sciences, Hokkaido University of Science, Sapporo, Japan
26 shared publicationsNobutaka Nagano
Division of Cardiovascular-Kidney-Metabolic Medicine, Department of Internal Medicine, Sapporo Medical University School of Medicine
24 shared publications- Hidemichi Kouzu
Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University School of Medicine, Sapporo 060-8543, Japan
23 shared publications Hidemichi Kouzu
Division of Cardiovascular-Kidney-Metabolic Medicine, Department of Internal Medicine, Sapporo Medical University School of Medicine
22 shared publicationsRyohei Nagaoka
Graduate School of Medicine, Sapporo Medical University
21 shared publications
Latest Publications
- Open Access
- 12 November 2026
- Published by Japanese Circulation Society in Circulation Reports
- p. CR-26-0283
Prospective Evaluation of Amino Acid Profiles and Physical Function Following Tofogliflozin Initiation in Adults With Type 2 Diabetes ― The TOFLEX Study Protocol ―
Background: Type 2 diabetes mellitus (T2DM) is associated with cardiometabolic dysfunction and progressive impairment of skeletal muscle health. Sodium–glucose cotransporter 2 inhibitors (SGLT2I) improve cardiovascular and renal outcomes, but their effects on amino acid metabolism, skeletal muscle composition, and physical function remain unclear. β-aminoisobutyric acid (BAIBA), a muscle-related amino acid, may link metabolic regulation with muscle health.Methods and Results: The TOFLEX study is a single-center, single-arm, prospective observational study evaluating longitudinal changes after initiation of tofogliflozin in adults with T2DM. Participants aged ≥18 years who are scheduled to start tofogliflozin in routine clinical care will be followed for 48 weeks. The primary outcome is the change in circulating amino acid concentrations, with particular attention to BAIBA. Secondary outcomes include changes in urinary amino acid profiles, physical function assessed by the Short Physical Performance Battery and handgrip strength, skeletal muscle mass assessed by dual-energy X-ray absorptiometry and bioelectrical impedance analysis, intramuscular fat infiltration assessed by magnetic resonance imaging and/or spectroscopy, and cardiometabolic parameters.Conclusions: TOFLEX will provide prospective data on amino acid remodeling after SGLT2i initiation and explore its relationship with skeletal muscle composition and physical function in adults with T2DM.
- 12 November 2026
- Published by Japanese Circulation Society in Circulation Reports
- p. CR-26-0283
Open AccessProspective Evaluation of Amino Acid Profiles and Physical Function Following Tofogliflozin Initiation in Adults With Type 2 Diabetes ― The TOFLEX Study Protocol ―
Background: Type 2 diabetes mellitus (T2DM) is associated with cardiometabolic dysfunction and progressive impairment of skeletal muscle health. Sodium–glucose cotransporter 2 inhibitors (SGLT2I) improve cardiovascular and renal outcomes, but their effects on amino acid metabolism, skeletal muscle composition, and physical function remain unclear. β-aminoisobutyric acid (BAIBA), a muscle-related amino acid, may link metabolic regulation with muscle health.Methods and Results: The TOFLEX study is a single-center, single-arm, prospective observational study evaluating longitudinal changes after initiation of tofogliflozin in adults with T2DM. Participants aged ≥18 years who are scheduled to start tofogliflozin in routine clinical care will be followed for 48 weeks. The primary outcome is the change in circulating amino acid concentrations, with particular attention to BAIBA. Secondary outcomes include changes in urinary amino acid profiles, physical function assessed by the Short Physical Performance Battery and handgrip strength, skeletal muscle mass assessed by dual-energy X-ray absorptiometry and bioelectrical impedance analysis, intramuscular fat infiltration assessed by magnetic resonance imaging and/or spectroscopy, and cardiometabolic parameters.Conclusions: TOFLEX will provide prospective data on amino acid remodeling after SGLT2i initiation and explore its relationship with skeletal muscle composition and physical function in adults with T2DM.
- Open Access
- 23 October 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (11) , 1692-1703
Altered Plasma Urea Cycle Metabolites Are Independently Associated With Frailty in Patients With Heart Failure
Background: Frailty is common in patients with heart failure and is associated with adverse outcomes. Although metabolic dysregulation has been implicated in frailty, the relationship between plasma amino acid profiles and frailty remains incompletely defined.Methods and Results: We conducted a single-center ambispective cross-sectional study of 413 patients hospitalized for heart failure (median age 78 years). Plasma concentrations of 31 amino acids were measured. Frailty status was assessed using the Japanese version of the Cardiovascular Health Study criteria. An unbiased analytical framework integrating multivariate analyses and multivariable logistic regression was applied with adjustment for heart failure severity, renal function, nutritional status, and body composition. Associations with all-cause mortality were evaluated using Cox models. Frailty was present in 228 (55%) patients. Unbiased analyses identified urea cycle-related metabolites as key features associated with frailty. In fully adjusted models, higher plasma citrulline and ornithine concentrations were independently associated with frailty, whereas arginine concentrations were not. These associations were independent of nutritional indices, skeletal muscle mass, and established prognostic factors. Neither citrulline nor ornithine was independently associated with mortality. Pathway analysis demonstrated enrichment of arginine biosynthesis and arginine–proline metabolism.Conclusions: Elevated citrulline and ornithine were independently associated with frailty in patients with heart failure, suggesting that dysregulated arginine-related metabolism may represent a metabolic signature of the frailty phenotype distinct from mortality risk.
- 23 October 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (11) , 1692-1703
Open AccessAltered Plasma Urea Cycle Metabolites Are Independently Associated With Frailty in Patients With Heart Failure
Background: Frailty is common in patients with heart failure and is associated with adverse outcomes. Although metabolic dysregulation has been implicated in frailty, the relationship between plasma amino acid profiles and frailty remains incompletely defined.Methods and Results: We conducted a single-center ambispective cross-sectional study of 413 patients hospitalized for heart failure (median age 78 years). Plasma concentrations of 31 amino acids were measured. Frailty status was assessed using the Japanese version of the Cardiovascular Health Study criteria. An unbiased analytical framework integrating multivariate analyses and multivariable logistic regression was applied with adjustment for heart failure severity, renal function, nutritional status, and body composition. Associations with all-cause mortality were evaluated using Cox models. Frailty was present in 228 (55%) patients. Unbiased analyses identified urea cycle-related metabolites as key features associated with frailty. In fully adjusted models, higher plasma citrulline and ornithine concentrations were independently associated with frailty, whereas arginine concentrations were not. These associations were independent of nutritional indices, skeletal muscle mass, and established prognostic factors. Neither citrulline nor ornithine was independently associated with mortality. Pathway analysis demonstrated enrichment of arginine biosynthesis and arginine–proline metabolism.Conclusions: Elevated citrulline and ornithine were independently associated with frailty in patients with heart failure, suggesting that dysregulated arginine-related metabolism may represent a metabolic signature of the frailty phenotype distinct from mortality risk.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e051493
Door‐to‐Cardiac Rehabilitation Time and Clinical Outcomes in Patients Hospitalized for Acute Heart Failure: A Nationwide Japanese Registry
Background: Cardiac rehabilitation (CR) improves outcomes in heart failure, but optimal initiation timing during acute hospitalization remains undefined. We characterized the dose–response association between door‐to‐cardiac rehabilitation time and in‐hospital outcomes, describing how this pattern appeared to differ between death and functional measures. Methods: Using the Japanese Registry of All Cardiac and Vascular Diseases–Diagnosis Procedure database, we identified 564 830 patients hospitalized for acute heart failure (2012–2023), categorized into non‐CR (n=275 454) and CR groups by door‐to‐cardiac rehabilitation quartiles: quartile 1 (≤1 day), quartile 2 (2–3 days), quartile 3 (4–5 days), and quartile 4 (≥6 days). Generalized propensity score–based weighting adjusted for 32 confounders. Restricted cubic splines evaluated dose–response patterns among CR recipients. The primary outcome was in‐hospital death; secondary outcomes were Barthel Index at discharge and Barthel Index improvement. Results: All door‐to‐cardiac rehabilitation quartiles showed lower in‐hospital death versus non‐CR (adjusted odds ratios, 0.39–0.49; all P <0.001). Barthel Index at discharge was higher in quartile 1 to quartile 3 (mean difference, +3.2 to +3.8 points), with a smaller difference in quartile 4. Spline analysis revealed nonlinear associations: The mortality nadir was observed at 6.1 days, whereas functional measures showed the most favorable associations at 3.3 days. Sensitivity analyses addressing immortal time bias yielded consistent mortality results. Conclusions: CR was associated with a lower in‐hospital mortality rate across all timing quartiles. The association pattern appeared to differ by outcome domain: Functional measures showed more favorable associations with earlier initiation (within 2–3 days), whereas a lower mortality rate was observed across a broader window. These findings warrant prospective evaluation.
- 6 October 2026
- Published by Wolters Kluwer Health in Journal of the American Heart Association
- Vol. 15 (19) , e051493
Door‐to‐Cardiac Rehabilitation Time and Clinical Outcomes in Patients Hospitalized for Acute Heart Failure: A Nationwide Japanese Registry
Background: Cardiac rehabilitation (CR) improves outcomes in heart failure, but optimal initiation timing during acute hospitalization remains undefined. We characterized the dose–response association between door‐to‐cardiac rehabilitation time and in‐hospital outcomes, describing how this pattern appeared to differ between death and functional measures. Methods: Using the Japanese Registry of All Cardiac and Vascular Diseases–Diagnosis Procedure database, we identified 564 830 patients hospitalized for acute heart failure (2012–2023), categorized into non‐CR (n=275 454) and CR groups by door‐to‐cardiac rehabilitation quartiles: quartile 1 (≤1 day), quartile 2 (2–3 days), quartile 3 (4–5 days), and quartile 4 (≥6 days). Generalized propensity score–based weighting adjusted for 32 confounders. Restricted cubic splines evaluated dose–response patterns among CR recipients. The primary outcome was in‐hospital death; secondary outcomes were Barthel Index at discharge and Barthel Index improvement. Results: All door‐to‐cardiac rehabilitation quartiles showed lower in‐hospital death versus non‐CR (adjusted odds ratios, 0.39–0.49; all P <0.001). Barthel Index at discharge was higher in quartile 1 to quartile 3 (mean difference, +3.2 to +3.8 points), with a smaller difference in quartile 4. Spline analysis revealed nonlinear associations: The mortality nadir was observed at 6.1 days, whereas functional measures showed the most favorable associations at 3.3 days. Sensitivity analyses addressing immortal time bias yielded consistent mortality results. Conclusions: CR was associated with a lower in‐hospital mortality rate across all timing quartiles. The association pattern appeared to differ by outcome domain: Functional measures showed more favorable associations with earlier initiation (within 2–3 days), whereas a lower mortality rate was observed across a broader window. These findings warrant prospective evaluation.
- Open Access
- 28 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4186
Genomic Architecture and Cascade Screening Gaps in Hypertrophic Cardiomyopathy: A Real-World Analysis
Background/Objectives: Hypertrophic cardiomyopathy (HCM) is genetically heterogeneous, involving more than 11 genes. Since HCM genetic testing was covered by Japan’s national health insurance in 2022, variant detection and the need for family-based intervention have increased, although funding is limited to symptomatic patients only. In this study, we evaluated institutional genetic testing outcomes, factors associated with pathogenic variants, and follow-up of at-risk relatives. Methods: We retrospectively analyzed individuals with confirmed or suspected HCM who underwent genetic testing between October 2022 and June 2025. Data regarding molecular results, family history of cardiomyopathy or sudden cardiac death in first-, second-, and third-degree relatives, and cascade screening were collected. Statistical analysis was performed using R version 2025.09.2 + 418. Results: Among 33 probands (median age, 54 years; 51% male), 13 individuals (39%) had pathogenic or likely pathogenic variants (PV or LPV), while six (18%) harbored variants of uncertain significance (VUS), and 14 (43%) yielded negative results. The PV or LPV cohort was significantly younger at the time of testing (median, 34 vs. 59 years; p = 0.008) and had a family history of PV or LPV (77% vs. 20%; p = 0.005). Only three relatives from two PV or LPV probands underwent cascade genetic screening; two tested positive and initiated targeted cardiac surveillance. Conclusions: Despite achieving actionable results, the restricted uptake of cascade screening highlights the need for improved communication and systemic support to facilitate family-based testing and precision medicine.
- 28 May 2026
- Published by MDPI AG in Journal of Clinical Medicine
- Vol. 15 (11) , 4186
Open AccessGenomic Architecture and Cascade Screening Gaps in Hypertrophic Cardiomyopathy: A Real-World Analysis
Background/Objectives: Hypertrophic cardiomyopathy (HCM) is genetically heterogeneous, involving more than 11 genes. Since HCM genetic testing was covered by Japan’s national health insurance in 2022, variant detection and the need for family-based intervention have increased, although funding is limited to symptomatic patients only. In this study, we evaluated institutional genetic testing outcomes, factors associated with pathogenic variants, and follow-up of at-risk relatives. Methods: We retrospectively analyzed individuals with confirmed or suspected HCM who underwent genetic testing between October 2022 and June 2025. Data regarding molecular results, family history of cardiomyopathy or sudden cardiac death in first-, second-, and third-degree relatives, and cascade screening were collected. Statistical analysis was performed using R version 2025.09.2 + 418. Results: Among 33 probands (median age, 54 years; 51% male), 13 individuals (39%) had pathogenic or likely pathogenic variants (PV or LPV), while six (18%) harbored variants of uncertain significance (VUS), and 14 (43%) yielded negative results. The PV or LPV cohort was significantly younger at the time of testing (median, 34 vs. 59 years; p = 0.008) and had a family history of PV or LPV (77% vs. 20%; p = 0.005). Only three relatives from two PV or LPV probands underwent cascade genetic screening; two tested positive and initiated targeted cardiac surveillance. Conclusions: Despite achieving actionable results, the restricted uptake of cascade screening highlights the need for improved communication and systemic support to facilitate family-based testing and precision medicine.
- Open Access
- 25 May 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (6) , 671-680
Sex-Specific Prognostic Patterns of Sarcopenia Components in Patients With Heart Failure
Background: Whether the components of sarcopenia provide sex-specific prognostic information in heart failure (HF) remains uncertain.Methods and Results: We enrolled 604 patients with HF (259 women; median age, 73 years) undergoing dual-energy X-ray absorptiometry. During 2.18-year follow-up, 124 deaths occurred. All sarcopenia components as continuous variables were associated with death in the overall cohort. Asian Working Group for Sarcopenia (AWGS2019) cutoffs for weak handgrip strength, prolonged fivetimes sittostand time (FTSS), or low Short Physical Performance Battery (SPPB) score showed the strongest association, whereas low appendicular skeletal muscle mass index (ASMI) did not predict death. No significant sex interactions were observed for ASMI, gait speed, FTSS, or SPPB, and only handgrip strength showed a borderline interaction trend (P=0.058), with a stronger association for death in women. Despite a nonsignificant interaction (P=0.284), the AWGS2019 criteria predicted death in men (adjusted HR, 2.23; 95% confidence interval (CI), 1.21–4.09, P=0.013) but not in women (aHR, 1.28; 95% CI, 0.70–2.34, P=0.423). Exploratory analyses showed that optimized, HF-specific ASMI thresholds improved prognostic performance.Conclusions: Performancebased sarcopenia components can provide valuable mortality risk stratification in HF irrespective of sex. Although sex interactions were limited, population-derived muscle mass thresholds showed reduced prognostic performance in women, indicating that refining disease-specific or sex-adapted thresholds may enhance risk stratification in HF.
- 25 May 2026
- Published by Japanese Circulation Society in Circulation Journal
- Vol. 90 (6) , 671-680
Open AccessSex-Specific Prognostic Patterns of Sarcopenia Components in Patients With Heart Failure
Background: Whether the components of sarcopenia provide sex-specific prognostic information in heart failure (HF) remains uncertain.Methods and Results: We enrolled 604 patients with HF (259 women; median age, 73 years) undergoing dual-energy X-ray absorptiometry. During 2.18-year follow-up, 124 deaths occurred. All sarcopenia components as continuous variables were associated with death in the overall cohort. Asian Working Group for Sarcopenia (AWGS2019) cutoffs for weak handgrip strength, prolonged fivetimes sittostand time (FTSS), or low Short Physical Performance Battery (SPPB) score showed the strongest association, whereas low appendicular skeletal muscle mass index (ASMI) did not predict death. No significant sex interactions were observed for ASMI, gait speed, FTSS, or SPPB, and only handgrip strength showed a borderline interaction trend (P=0.058), with a stronger association for death in women. Despite a nonsignificant interaction (P=0.284), the AWGS2019 criteria predicted death in men (adjusted HR, 2.23; 95% confidence interval (CI), 1.21–4.09, P=0.013) but not in women (aHR, 1.28; 95% CI, 0.70–2.34, P=0.423). Exploratory analyses showed that optimized, HF-specific ASMI thresholds improved prognostic performance.Conclusions: Performancebased sarcopenia components can provide valuable mortality risk stratification in HF irrespective of sex. Although sex interactions were limited, population-derived muscle mass thresholds showed reduced prognostic performance in women, indicating that refining disease-specific or sex-adapted thresholds may enhance risk stratification in HF.
- Open Access
- 10 February 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Prognostic value of skeletal muscle viscoelasticity in older patients with heart failure: the VISMARC-HF study design
Sarcopenia affects 16–57% of patients with heart failure (HF) and worsens prognosis. Current assessments relying on muscle mass and strength are conf
- 10 February 2026
- Published by Springer Nature in BMC Geriatrics
- Vol. 26 (1)
Open AccessPrognostic value of skeletal muscle viscoelasticity in older patients with heart failure: the VISMARC-HF study design
Sarcopenia affects 16–57% of patients with heart failure (HF) and worsens prognosis. Current assessments relying on muscle mass and strength are conf
- Open Access
- 11 November 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (1) , 73-82
Protective association of renin‐angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure
Aims: Muscle wasting is common in heart failure (HF) patients, particularly those with diabetes mellitus (DM). Renin‐angiotensin system inhibitors (RASI) may have muscle‐protective effects, but their association with muscle wasting in diabetic HF patients remains unclear. We investigated whether the association between RASI use and muscle wasting differs by DM status and plasma 3‐methylhistidine (3‐Me‐His) levels, a muscle protein breakdown biomarker. Materials and Methods: We performed a cross‐sectional analysis of 384 hospitalized HF patients (mean age 71 ± 14 years, 41% female, 38% with DM). Muscle wasting was defined by dual‐energy X‐ray absorptiometry according to the Asian Working Group for Sarcopenia criteria. Associations between RASI use and muscle wasting were evaluated using logistic regression with inverse probability of treatment weighting. Interaction analyses assessed effect modification by DM status and 3‐Me‐His levels. Results: Muscle wasting prevalence was 58%. DM was an independent risk factor for muscle wasting (adjusted odds ratio [OR] 2.07, 95% confidence interval [CI] 1.27–3.38, P = 0.004). RASI were prescribed in 52% of patients. After adjustment, a significant interaction with DM was observed ( P = 0.033). Among DM patients, RASI use was associated with lower muscle wasting (OR 0.33, 95% CI 0.14–0.76, P = 0.010), while no association was found in non‐DM patients. Within the DM subgroup, the association was more evident in patients with lower 3‐Me‐His levels (OR 0.12, 95% CI 0.03–0.52, P = 0.005). Conclusions: RASI use was associated with significantly lower muscle wasting in HF patients with DM, particularly those with lower 3‐Me‐His levels. These findings suggest a potential therapeutic window and warrant prospective investigation.
- 11 November 2025
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 17 (1) , 73-82
Open AccessProtective association of renin‐angiotensin system inhibitor use with skeletal muscle wasting in diabetic heart failure
Aims: Muscle wasting is common in heart failure (HF) patients, particularly those with diabetes mellitus (DM). Renin‐angiotensin system inhibitors (RASI) may have muscle‐protective effects, but their association with muscle wasting in diabetic HF patients remains unclear. We investigated whether the association between RASI use and muscle wasting differs by DM status and plasma 3‐methylhistidine (3‐Me‐His) levels, a muscle protein breakdown biomarker. Materials and Methods: We performed a cross‐sectional analysis of 384 hospitalized HF patients (mean age 71 ± 14 years, 41% female, 38% with DM). Muscle wasting was defined by dual‐energy X‐ray absorptiometry according to the Asian Working Group for Sarcopenia criteria. Associations between RASI use and muscle wasting were evaluated using logistic regression with inverse probability of treatment weighting. Interaction analyses assessed effect modification by DM status and 3‐Me‐His levels. Results: Muscle wasting prevalence was 58%. DM was an independent risk factor for muscle wasting (adjusted odds ratio [OR] 2.07, 95% confidence interval [CI] 1.27–3.38, P = 0.004). RASI were prescribed in 52% of patients. After adjustment, a significant interaction with DM was observed ( P = 0.033). Among DM patients, RASI use was associated with lower muscle wasting (OR 0.33, 95% CI 0.14–0.76, P = 0.010), while no association was found in non‐DM patients. Within the DM subgroup, the association was more evident in patients with lower 3‐Me‐His levels (OR 0.12, 95% CI 0.03–0.52, P = 0.005). Conclusions: RASI use was associated with significantly lower muscle wasting in HF patients with DM, particularly those with lower 3‐Me‐His levels. These findings suggest a potential therapeutic window and warrant prospective investigation.
- Open Access
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9347
Cardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying hypercontractility at the sarcomere level. Recent advances in molecular understanding have led to the development of cardiac myosin inhibitors that directly modulate sarcomeric function by reducing myosin–actin cross-bridge formation and adenosine triphosphatase (ATPase) activity. Mavacamten and aficamten have shown promising results in phase 2 and 3 clinical trials, improving symptoms, exercise capacity, and left ventricular outflow tract gradients in patients with obstructive HCM. This review summarizes the current understanding of HCM pathophysiology, diagnostic strategies, and conventional treatments with a focus on the mechanisms of action of myosin inhibitors, clinical evidence supporting their use, and future directions for improvement. We also discuss their potential applications in non-obstructive HCM and the importance of precision medicine guided by genetic profiling.
- 24 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (19) , 9347
Open AccessCardiac Myosin Inhibitors in Hypertrophic Cardiomyopathy: From Sarcomere to Clinic
Hypertrophic cardiomyopathy (HCM) is a primary myocardial disease characterized by unexplained left ventricular hypertrophy, often resulting from pathogenic variants of sarcomeric protein genes. Conventional treatments, such as the use of beta blockers or calcium channel blockers, focus on symptomatic control but do not address the underlying hypercontractility at the sarcomere level. Recent advances in molecular understanding have led to the development of cardiac myosin inhibitors that directly modulate sarcomeric function by reducing myosin–actin cross-bridge formation and adenosine triphosphatase (ATPase) activity. Mavacamten and aficamten have shown promising results in phase 2 and 3 clinical trials, improving symptoms, exercise capacity, and left ventricular outflow tract gradients in patients with obstructive HCM. This review summarizes the current understanding of HCM pathophysiology, diagnostic strategies, and conventional treatments with a focus on the mechanisms of action of myosin inhibitors, clinical evidence supporting their use, and future directions for improvement. We also discuss their potential applications in non-obstructive HCM and the importance of precision medicine guided by genetic profiling.
- Open Access
- 12 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8913
Imeglimin Alleviates High-Glucose-Induced Bioenergetic and Oxidative Stress Thereby Enhancing Intercellular Adhesion in H9c2 Cardiomyoblasts
To elucidate the effects of the new antidiabetic agent, imeglimin (Ime, 2 mM), on high-glucose-induced cellular stress in cardiac cells, its effects were compared with those of the conventional antidiabetic agent metformin (Met, 2 mM) based on various cellular pathophysiological functions. H9c2 cardiomyoblasts were cultured under normal-glucose (5.5 mM, N-Glu) or high-glucose (50 mM, H-Glu) conditions. Cellular metabolic function was evaluated using a Seahorse XFe96 Bioanalyzer, along with measurements of reactive oxygen species (ROS) production, expression levels of the autophagy-related marker LC3, and intercellular adhesion properties measured based on transepithelial electrical resistance (TEER). Cells cultured under H-Glu conditions showed enhanced mitochondrial and glycolytic activities, which were suppressed by Met or Ime. Under H-Glu conditions, total cellular ROS (t-ROS) levels were significantly increased. Met had little effect on t-ROS under H-Glu conditions, whereas Ime markedly reduced both t-ROS and mitochondrial ROS (m-ROS) levels under H-Glu conditions. The LC3-II/LC3-I ratio, a marker of autophagic activity, decreased under H-Glu conditions; however, this reduction was not significantly affected by treatment with either Met or Ime. Regarding intercellular adhesion properties, TEER values were elevated under H-Glu conditions compared to N-Glu conditions, and those under H-Glu conditions were further increased by Ime but not Met. In support of these results, the mRNA levels of cell-adhesion-related molecules, including β-catenin and N-cadherin, were also altered by Ime. Collectively, Ime modulated high-glucose-induced alterations in the biological properties of H9c2 cardiomyoblasts, independent of changes in autophagic activity.
- 12 September 2025
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (18) , 8913
Open AccessImeglimin Alleviates High-Glucose-Induced Bioenergetic and Oxidative Stress Thereby Enhancing Intercellular Adhesion in H9c2 Cardiomyoblasts
To elucidate the effects of the new antidiabetic agent, imeglimin (Ime, 2 mM), on high-glucose-induced cellular stress in cardiac cells, its effects were compared with those of the conventional antidiabetic agent metformin (Met, 2 mM) based on various cellular pathophysiological functions. H9c2 cardiomyoblasts were cultured under normal-glucose (5.5 mM, N-Glu) or high-glucose (50 mM, H-Glu) conditions. Cellular metabolic function was evaluated using a Seahorse XFe96 Bioanalyzer, along with measurements of reactive oxygen species (ROS) production, expression levels of the autophagy-related marker LC3, and intercellular adhesion properties measured based on transepithelial electrical resistance (TEER). Cells cultured under H-Glu conditions showed enhanced mitochondrial and glycolytic activities, which were suppressed by Met or Ime. Under H-Glu conditions, total cellular ROS (t-ROS) levels were significantly increased. Met had little effect on t-ROS under H-Glu conditions, whereas Ime markedly reduced both t-ROS and mitochondrial ROS (m-ROS) levels under H-Glu conditions. The LC3-II/LC3-I ratio, a marker of autophagic activity, decreased under H-Glu conditions; however, this reduction was not significantly affected by treatment with either Met or Ime. Regarding intercellular adhesion properties, TEER values were elevated under H-Glu conditions compared to N-Glu conditions, and those under H-Glu conditions were further increased by Ime but not Met. In support of these results, the mRNA levels of cell-adhesion-related molecules, including β-catenin and N-cadherin, were also altered by Ime. Collectively, Ime modulated high-glucose-induced alterations in the biological properties of H9c2 cardiomyoblasts, independent of changes in autophagic activity.
- Open Access
- 1 August 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (5) , 3589-3600
Diagnostic Value of Computed Tomography-Based Muscle Quality and Metabolic Signatures in Heart Failure with Sarcopenia
Aims: Sarcopenia is a major comorbidity in heart failure (HF) patients, but its comprehensive evaluation remains challenging due to resource limitations. Computed tomography (CT) imaging allows opportunistic assessment of both muscle quantity and quality; however, its diagnostic utility and relationships with physical performance and underlying metabolic alterations remain unclear. We investigated the diagnostic utility of single-slice abdominal CT for sarcopenia assessment and explored its association with plasma amino acid profiles in HF patients. Methods and results: We retrospectively analysed 212 HF patients (73 ± 13 years old; 41% females) who underwent dual-energy X-ray absorptiometry (DXA), abdominal CT imaging, and amino acid profiling, of whom 186 had complete sarcopenia assessment. Sarcopenia was diagnosed based on the Asian Working Group for Sarcopenia 2019 criteria using DXA-measured appendicular skeletal muscle mass index and grip strength, with severe sarcopenia additionally requiring low Short Physical Performance Battery scores. CT-measured skeletal muscle area index (SMI) at the lumbar vertebral level combined with grip strength showed high diagnostic accuracy for sarcopenia [area under the receiver operating characteristic curve (AUC): 0.96 for males, 0.88 for females], with optimal cut-off values of 54 cm2/m2 for males and 40 cm2/m2 for females. SMI was similarly reduced in non-severe and severe sarcopenia patients, whereas mean muscle attenuation (MMA), an index of intramuscular lipid infiltration, was decreased exclusively in patients with severe sarcopenia. In multivariable analysis adjusted for age, sex, HF functional class and diabetes, decreased MMA remained the only CT-measured index significantly associated with low physical performance. MMA showed higher predictive value than SMI for severe sarcopenia in males (AUC 0.81 vs. 0.54, P = 0.039). Several amino acids (leucine, β-alanine and 3-methylhistidine) and the Fischer ratio were significantly associated with MMA, independent of SMI and established MMA determinants including sex, age, and body mass index. Conclusions: Single-slice abdominal CT provides accurate sarcopenia diagnosis in HF patients with reduced muscle strength, with muscle quality rather than quantity determining physical performance. Specific amino acid profiles associated with muscle quality changes suggest potential therapeutic targets for preventing sarcopenia progression.
- 1 August 2025
- Published by Oxford University Press (OUP) in ESC Heart Failure
- Vol. 12 (5) , 3589-3600
Open AccessDiagnostic Value of Computed Tomography-Based Muscle Quality and Metabolic Signatures in Heart Failure with Sarcopenia
Aims: Sarcopenia is a major comorbidity in heart failure (HF) patients, but its comprehensive evaluation remains challenging due to resource limitations. Computed tomography (CT) imaging allows opportunistic assessment of both muscle quantity and quality; however, its diagnostic utility and relationships with physical performance and underlying metabolic alterations remain unclear. We investigated the diagnostic utility of single-slice abdominal CT for sarcopenia assessment and explored its association with plasma amino acid profiles in HF patients. Methods and results: We retrospectively analysed 212 HF patients (73 ± 13 years old; 41% females) who underwent dual-energy X-ray absorptiometry (DXA), abdominal CT imaging, and amino acid profiling, of whom 186 had complete sarcopenia assessment. Sarcopenia was diagnosed based on the Asian Working Group for Sarcopenia 2019 criteria using DXA-measured appendicular skeletal muscle mass index and grip strength, with severe sarcopenia additionally requiring low Short Physical Performance Battery scores. CT-measured skeletal muscle area index (SMI) at the lumbar vertebral level combined with grip strength showed high diagnostic accuracy for sarcopenia [area under the receiver operating characteristic curve (AUC): 0.96 for males, 0.88 for females], with optimal cut-off values of 54 cm2/m2 for males and 40 cm2/m2 for females. SMI was similarly reduced in non-severe and severe sarcopenia patients, whereas mean muscle attenuation (MMA), an index of intramuscular lipid infiltration, was decreased exclusively in patients with severe sarcopenia. In multivariable analysis adjusted for age, sex, HF functional class and diabetes, decreased MMA remained the only CT-measured index significantly associated with low physical performance. MMA showed higher predictive value than SMI for severe sarcopenia in males (AUC 0.81 vs. 0.54, P = 0.039). Several amino acids (leucine, β-alanine and 3-methylhistidine) and the Fischer ratio were significantly associated with MMA, independent of SMI and established MMA determinants including sex, age, and body mass index. Conclusions: Single-slice abdominal CT provides accurate sarcopenia diagnosis in HF patients with reduced muscle strength, with muscle quality rather than quantity determining physical performance. Specific amino acid profiles associated with muscle quality changes suggest potential therapeutic targets for preventing sarcopenia progression.